Skip to main content
SpringerLink
Log in

Intra-arterial Therapy of Liver Tumours

  • Chapter
Clinical Nuclear Medicine

  • 2530 Accesses

Abstract

Hepatocellular carcinoma (HCC) is one of the most frequent cancers worldwide; in fact, it is ranked fifth in importance with approximately 437,000 new cases per annum (Bosch et al. 1999). Its incidence is increasing in many countries (Trinchet and Beaugrand 1999; Taylor-Robinson et al. 1997; Deuffic and Poynard 1998; El-Serag and Mason 1999). The first recognized risk factor is the presence of a cirrhosis that may be associated with various possible aetiologies (B and C viral infections, alcohol, haemochromatosis). This increased incidence is related to the better health care of patients suffering from cirrhosis, but also to a strong increase in chronic hepatitis C (Trinchet and Beaugrand 1999; Taylor-Robinson et al. 1997; Deuffic and Poynard 1998; Okuda 2000). Indeed, in France, approximately 500,000 people would appear to be infected by the hepatitis C virus (Trinchet and Beaugrand 1999). It is estimated that about 66 % present with chronic hepatitis and that 20 % will develop cirrhosis in 10–20 years in the absence of treatment. In France, it is estimated that the mortality linked to HCC occurring with hepatitis C virus cirrhosis will increase by 150% in men and 200% in women from now until 2020 (Deuffic et al. 1999). We may thus consider that, in the years to come, HCC will pose a problem for public health.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abrams RA, et al. (1998) Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center. Cancer J Sci Am 4(3):178–184

    PubMed  CAS  Google Scholar 

  • Amin AE, et al. (1993) Radiobiological modeling of combined targeted 1311 therapy and total body irradiation for treatment of disseminated tumors of differing radiosensitivity. Int J Radiat Oncol Biol Phys 27:323–330

    PubMed  CAS  Google Scholar 

  • Andrews JC, et al. (1994) Hepatic radioembolisation with yttri-um-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 35:1637–1644

    PubMed  CAS  Google Scholar 

  • Ariel IM, Padula G (1978) Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intra-arterial administration of chemotherapy and radioactive isotopes. J Surg Oncol 10:327–336

    PubMed  CAS  Google Scholar 

  • Arii S, et al. (2001) Characteristics of recurrent hepatocellular carcinoma in Japan and our surgical experience. J Hepatobiliary Pancreat Surg 8:397–403

    PubMed  CAS  Google Scholar 

  • Bacher K, et al. (2002) Thyroid uptake and radiation dose after 1311-lipiodol treatment: is thyroid blocking by potassium iodide necessary? Eur J Nucl Med 29:1311–1316

    CAS  Google Scholar 

  • Badvie S (2000) Hepatocellular carcinoma. Postgrad Med J 76:4–11

    PubMed  CAS  Google Scholar 

  • Behr TM, et al. (1997) Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 38(6):858–870

    PubMed  CAS  Google Scholar 

  • Behr TM, et al. (1999) Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of aphase I clinical study. Clin Cancer Res 5(10 Suppl):3232s–3242s

    PubMed  CAS  Google Scholar 

  • Behr TM, et al. (2002) Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 94(4 Suppl):1373–1381

    PubMed  CAS  Google Scholar 

  • Bhattacharya S, et al. (1995) Epirubicin-Lipiodol chemotherapy versus 131iodine-lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 76:2202–2210

    PubMed  CAS  Google Scholar 

  • Bosch FX, et al. (1999) Epidemiology of primary liver cancer. Semin Liver Dis 19(3):271–285

    PubMed  CAS  Google Scholar 

  • Boschi A, et al. (2004) A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nucl Med Comm 25(7):691–699

    CAS  Google Scholar 

  • Boucher E, et al. (2003) Adjuvant intra-arterial injection of iodine-131-labelled lipiodol after resection of hepatocellular carcinoma. Hepatology 38:1237–1241

    PubMed  CAS  Google Scholar 

  • Brans B, et al. (2001) The anti-tumoral activity of neoadjuvant intra-arterial 1311-Lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biother Radiopharm 4:333–338

    Google Scholar 

  • Brans B, et al. (2002) Combined iodine-131 lipiodol therapy with low-dose cisplatin as radiosensitiser: preliminary study results in hepatocellular carcinoma. Eur J Nucl Med 29:928–932

    CAS  Google Scholar 

  • Brans B, et al. (2003) Intra-arterial radionuclide therapy for liver tumours: effect of selectivity of catheterization and 1311-lipiodol delivery on tumor uptake and response. Nucl Med Comm 24:391–396

    CAS  Google Scholar 

  • Bretagne JF, et al. (1988) Hepatic artery injection of I-131-la-beled Lipiodol. Radiology 168:547–550

    PubMed  CAS  Google Scholar 

  • Bronowiki JP, et al. (1994) Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 74:16–24

    Google Scholar 

  • Bruix J, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35:421–430

    PubMed  CAS  Google Scholar 

  • Burton MA, et al. (1985) Manipulation of experimental rat and rabbit liver tumor blood flow with angiotensin II. Cancer Res 45:5390–5393

    PubMed  CAS  Google Scholar 

  • Burton MA, et al. (1988) Effect of angiotensin II on blood flow in the transplanted sheep squamous cell carcinoma. Eur J Cancer Clin Oncol 24:1373–1376

    PubMed  CAS  Google Scholar 

  • Calvet X, et al. (1990) Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 12:753–760

    PubMed  CAS  Google Scholar 

  • Cao X, et al. (1999) Hepatic radioembolisation with yttrium-90 glass microspheres for treatment of primary liver cancer. Chinese Med J 112(5):430–432

    CAS  Google Scholar 

  • Chen S, et al. (2004) Phase I clinical trial of targeted therapy using 131I-Hepama-l mAb in patients with hepatocellular carcinoma. Cancer Biother Radiopharm 19(5):589–600

    PubMed  CAS  Google Scholar 

  • Chenoufi N, et al. (1998) In vitro demonstration of synergy between radionuclide and chemotherapy. J Nucl Med 39:900–903

    PubMed  CAS  Google Scholar 

  • Chlebowski RT, et al. (1984) Hepatocellular carcinoma, diagnostic and prognostic features in North American patients. Cancer 53:2701–2706

    PubMed  CAS  Google Scholar 

  • Chou FI, et al. (1994) 1-131-lipiodol cytotoxicity in hepatoma cells. Proc Natl Sci Council ROC 18:154–160

    CAS  Google Scholar 

  • Chou FI, et al. (1995) Lipiodol uptake and retention by human hepatoma cells. Nucl Med Biol 22(3):379–386

    PubMed  CAS  Google Scholar 

  • Dancey JE, et al. (2000) Treatment of non resectable hepatocellular carcinoma with intrahepatic 90yttrium microspheres. J Nucl Med 41:1673–1681

    PubMed  CAS  Google Scholar 

  • De Baere T, et al. (1996) Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. Radiology 201:731–735

    PubMed  Google Scholar 

  • De Baere, et al. (1999) Hepatic intraarterial 131I iodized oil for treatment of hepatocellular carcinoma in patient with impeded portal venous flow. Radiology 212:665–668

    PubMed  Google Scholar 

  • De Sanctis JT, et al. (1998) Percutaneous treatment of hepatic neoplasms: a review of the current techniques. Cardiovasc Intervent Radiol 21:273–296

    PubMed  Google Scholar 

  • Deuffic S, Poynard T (1998) Trends in primary liver cancer. Lancet 351:214–215

    PubMed  CAS  Google Scholar 

  • Deuffic S, et al. (1999) Modelling the hepatitis C virus epidemic in France. Hepatology 29:1596–1601

    PubMed  CAS  Google Scholar 

  • El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750

    PubMed  CAS  Google Scholar 

  • Fan Z, et al. (1992) Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin. Targeting therapy, tumor imaging and anti-antibody response in patients with hepatic arterial infusion. J Cancer Res Clin Oncol 118:371–376

    PubMed  CAS  Google Scholar 

  • Garin E, et al. (2003) Safe radiation exposure of medical personnel using simple radioprotection means while administering 131I-lipiodol therapy for hepatocellular carcinoma. Nucl Med Comm 24:671–678

    CAS  Google Scholar 

  • Garin E, et al. (2004a) 188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma. Nucl Med Comm 25:1007–1013

    CAS  Google Scholar 

  • Garin E, et al. (2004b) Development and biodistribution of 188Re-SSS lipiodol following injection into hepatic artery of healthy pig. Eur J Nucl Med Mol Imaging 31:542–546

    PubMed  CAS  Google Scholar 

  • Garin E, et al. (2005) Effect of stabilized lipiodol emulsion on experimentally induced hepatocellular carcinoma in rats. J Vasc Intervent Radiol 16(6):849–856

    Google Scholar 

  • Goin JE, et al. (2005) Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 16(2):195–203

    PubMed  Google Scholar 

  • Grady ED (1979) Internal radiation therapy of hepatic cancer. Dis Col Rect 22(6):371–375

    CAS  Google Scholar 

  • Gray BN, et al. (1989) Selective internal radiation (SIR) therapy for treatment of liver metastases: measurement of response rate. J Surg Oncol 42:192–196

    PubMed  CAS  Google Scholar 

  • Gray BN, et al. (1990) Tolerance of the liver to the effects of yt-trium-90 radiation. Int J Radiat Oncol Biol Phys 18:619–623

    PubMed  CAS  Google Scholar 

  • Gray BN, et al. (1992) Regression of liver metastases following treatment with yttrium-90 microspheres. Austr N Z J Surg 62:105–110

    Article  CAS  Google Scholar 

  • Gray BN, et al. (2000) Treatment of colorectal liver metastases with SIR-spheres plus chemotherapy. GI Cancer 3(4):249–257

    Google Scholar 

  • Gray BN, et al. (2001) Randomized trial of SIR-spheres® plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:1711–1720

    PubMed  CAS  Google Scholar 

  • Groupe d’étude et de traitement du carcinome hépatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261

    Google Scholar 

  • Hamuro M, et al. (1999) New oily agents for targeting chemoembolisation for hepatocellular carcinoma. Cardiovasc Int Radiol 22:130–134

    CAS  Google Scholar 

  • Herba MJ, et al. (1988) Hepatic malignancies: improved treatment with intraarterial Y-90. Radiology 169:311–314

    PubMed  CAS  Google Scholar 

  • Hind RE, et al. (1992) Biodistribution of Lipiodol following hepatic arterial injection. Br J Surg 79:952–954

    PubMed  CAS  Google Scholar 

  • Ho S, et al. (1996) Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 23:947–952

    PubMed  CAS  Google Scholar 

  • Ho S, et al. (1997a) Arteriovenous shunts in patients with hepatic tumors. J Nucl Med 38:1201–1205

    PubMed  CAS  Google Scholar 

  • Ho S, et al. (1997b) Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancers. Eur J Nucl Med 24:293–298

    PubMed  CAS  Google Scholar 

  • Ho S, et al. (1998) Internal radiation therapy for patients with primary or metastatic hepatic cancer. Cancer 83:1894–1907

    PubMed  CAS  Google Scholar 

  • Ho S, et al. (2001) Intrahepatic 90Y-microspheres for hepatocellular carcinoma. Eur J Nucl Med 42:1587–1589

    CAS  Google Scholar 

  • Houle, et al. (1989) Hepatocellular carcinoma: a pilot trial of treatment with Y-90 microspheres. Radiology 172:857–860

    PubMed  CAS  Google Scholar 

  • Humm JL (1986) Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 27:1490–1497

    PubMed  CAS  Google Scholar 

  • Ingold JA, et al. (1965) Radiation hepatitis. Am J Roentgen Radium Ther Nucl Med 93:200–208.

    CAS  Google Scholar 

  • Iwai K, et al. (1984) Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res 44:2115–2121

    PubMed  CAS  Google Scholar 

  • Jeong JM, et al. (2001) Lipiodol solution of a lipophilic agent, 188Re-TDD, for the treatment of liver cancer. Nucl Med Biol 28:197–204

    PubMed  CAS  Google Scholar 

  • Kaczynski, et al. (1998) Spontaneous regression of HCC. Histopathology 32:147–150

    PubMed  CAS  Google Scholar 

  • Kajiya Y, et al. (1993) Transarterial internal radiation therapy with 1-131 lipiodol for multifocal hepatocellular carcinoma: intermediate and long term results. Cardiovasc Intervent Radiol 16:150–157

    PubMed  CAS  Google Scholar 

  • Kan Z (1996) Dynamic study of iodized oil in the liver and blood supply to hepatic tumors. An experimental investigation in several animal species. Acta Radiol 37(Suppl):6–25

    Google Scholar 

  • Kan Z, et al. (1989) In vivo microscopy of the liver after injection of lipiodol into the hepatic artery and portal vein in the rat. Acta Radiol 30:419–425

    PubMed  CAS  Google Scholar 

  • Kinuya S, et al. (2004) Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy. Eur J Nucl Med Mol Imaging 31(7):981–985

    PubMed  CAS  Google Scholar 

  • Klein JL, et al. (1989) Yttrium 90 and iodine 131 radioimmunoglobulin therapy of an experimental human hepatoma. Cancer Res 49:6383–6389

    PubMed  CAS  Google Scholar 

  • Knapp FF, Jr, et al. (1994) Processing of reactor-produced 188W for fabrication of clinical scale alumina-based 188W/188Re generators. Appl Radiat Isot 45:1123–1128

    CAS  Google Scholar 

  • Kobayashi H, et al. (1986) Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diag 27:139–147

    CAS  Google Scholar 

  • Kobayashi H, et al. (1987) Intra-arterial injection of adriamycin/mitomicin C Lipiodol suspension in liver metastases. Acta Radiologica 28:275–280

    Article  PubMed  CAS  Google Scholar 

  • Konno T, et al. (1984) Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54:2367–2374

    PubMed  CAS  Google Scholar 

  • Kouroumalis E, et al. (1998) Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42:442–447

    Article  PubMed  CAS  Google Scholar 

  • Lambert B, et al. (2005) 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med 46(l):60–66

    PubMed  CAS  Google Scholar 

  • Lau WY (2002) Management of hepatocellular carcinoma. J R Coll Surg Edinb 47:389–399

    PubMed  CAS  Google Scholar 

  • Lau WY, et al. (1994) Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 70:994–999

    PubMed  CAS  Google Scholar 

  • Lau WY, et al. (1998) Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40(3):583–592

    PubMed  CAS  Google Scholar 

  • Lau WY, et al. (1999) Adjuvant intra-arterial iodine-131-la-belled Lipiodol for respectable hepatocellular carcinoma: a prospective randomized trial. Lancet 353:797–801

    PubMed  CAS  Google Scholar 

  • Lee YS, et al. (2002) Synthesis of 188Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Comm 23:237–242

    CAS  Google Scholar 

  • Leichner PK, et al. (1984) Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti AFP, and anti-CEA in primary liver cancers. Cancer Drug Delivery 1(4):321–328

    PubMed  CAS  Google Scholar 

  • Leichner PK, et al. (1988) Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma. Int J Radiat Oncol Biol Phys 14:1033–1042

    PubMed  CAS  Google Scholar 

  • Lepareur N, et al. (2004) A kit formulation for the labelling of Lipiodol with generator-produced 188Re. J Label Compounds Radiopharm 47:857–867

    CAS  Google Scholar 

  • Leung TWT, et al. (1994) Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 35:1313–1318

    PubMed  CAS  Google Scholar 

  • Leung TWT, et al. (1995) Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttriummicrospheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33:19–24

    Google Scholar 

  • Leung TWT, et al. (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676–1681

    PubMed  CAS  Google Scholar 

  • Leung TWT, Johnson PJ (2001) Systemic therapy for hepatocellular carcinoma. Semin Oncol 28:514–520

    PubMed  CAS  Google Scholar 

  • Levy I, Sherman M (2002) Staging of hepatocellular carcinoma: assessment of the Clip, Okuda and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 50:881–885

    PubMed  CAS  Google Scholar 

  • Li XF, et al. (2002) Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells. Eur J Nucl Med Mol Imaging 29(12):1669–1674

    PubMed  CAS  Google Scholar 

  • Liu KD, et al. (1989) Radioimmunotherapy for hepatocellular carcinoma (HCC) using 131I-anti HCC isoferritin IgG: preliminary results of experimental and clinical studies. Int J Radiat Oncol Biol Phys 16:319–323

    PubMed  CAS  Google Scholar 

  • Liu MD, et al. (2004) Use of yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. Am Surg 70(11):947–953

    PubMed  Google Scholar 

  • Llovet JM, et al. (1999) Natural history of untreated non surgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29:62–67

    PubMed  CAS  Google Scholar 

  • Llovet JM, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739

    PubMed  Google Scholar 

  • Lo CM, et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171

    PubMed  CAS  Google Scholar 

  • Lui WY, et al. (1990) Report of a pilot study of intra-arterial injection of 1-131 Lipiodol for the treatment of hepatoma. Chin Med J (Taipei) 46:125–133

    CAS  Google Scholar 

  • Luo TY, et al. (2004) Preparation and biodistribution of rhenium-188 ECD/lipiodol in rats following hepatic arterial injection. Nucl Med Biol 31:671–677

    PubMed  CAS  Google Scholar 

  • Madden MV, et al. (1993) Randomised trial of targeted chemotherapy with lipiodol and epidoxorubicin compared with symptomatic treatment hepatoma. Gut 34:1598–1600

    PubMed  CAS  Google Scholar 

  • Madsen MT, et al. (1988) Dosimetry of iodine 131 ethiodol in the treatment of hepatoma. J Nucl Med 29:1038–1044

    PubMed  CAS  Google Scholar 

  • Maini CL, et al. (1996) Superselective intra-arterial radiometabolic therapy with 1-131 Lipiodol in hepatocellular carcinoma. Clin Nucl Med 21:221–226

    PubMed  CAS  Google Scholar 

  • Maki S, et al. (1985) Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 56(4):751–757

    PubMed  CAS  Google Scholar 

  • Mantravadi RVP, et al. (1982) Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology 142:783–786

    PubMed  CAS  Google Scholar 

  • Margolis LW, Phillips TL (1969) Whole lung irradiation for metastatic tumor. Radiology 93:1173–1179

    PubMed  CAS  Google Scholar 

  • Maublant J, et al. (2001) Médecine nucléaire en oncologie: nouvelles modalités diagnostiques et thérapeutiques. Bull Cancer 88:35–44

    PubMed  CAS  Google Scholar 

  • Mazeron JJ, et al. (1991) Influence of dose rate on local control of breast carcinoma treated by external beam irradiation plus iridium 192 implant. Int J Radiat Oncol Biol Phys 21:1173–1177

    PubMed  CAS  Google Scholar 

  • Miller DL, et al. (1987) Distribution of iodized oil within the liver after hepatic arterial injection. Radiology 162:849–852

    PubMed  CAS  Google Scholar 

  • Monsieur MA, et al. (2003) Patient dosimetry for 131I-lipiodol therapy. Eur J Nucl Med 30:554–561

    Article  CAS  Google Scholar 

  • Nakajo M, et al. (1988) Biodistribution and in vivo kinetics of iodine 131 Lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med 29:1066–1077

    PubMed  CAS  Google Scholar 

  • Nakakuma K, et al. (1983) Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 52:2193–2200

    PubMed  CAS  Google Scholar 

  • Nakakuma K, et al. (1985) Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology 154:15–17

    PubMed  CAS  Google Scholar 

  • O’Donoghue JA, et al. (1995) Relationship between tumor size and curability for uniformly targeted therapy with betaemitting radionuclides. J Nucl Med 36:1902–1909

    PubMed  CAS  Google Scholar 

  • Okuda K (2000) Hepatocellular carcinoma. J Hepatol 32(Suppl l):225–237

    PubMed  CAS  Google Scholar 

  • Order SE, et al. (1985) Iodine 131 antiferritin, a newtreatment modality in hepatoma: a radiation therapy oncology group study. J Clin Oncol 3:1573–1582

    PubMed  CAS  Google Scholar 

  • Order SE, et al. (1986) 90yttrium antiferritin–a new therapeutic radiolabeled antibody. Int J Radiat Oncol Biol Phys 12:277–281

    PubMed  CAS  Google Scholar 

  • Order SE, et al. (1991) A randomized prospective trial comparing full dose chemotherapy to 1311 antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys 20:953–963

    PubMed  CAS  Google Scholar 

  • Otto G, et al. (1998) Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma, a retrospective analysis. Ann Surg 227:424–432

    PubMed  CAS  Google Scholar 

  • Paeng JC, et al. (2003) Lipiodol solution of 188Re-HDD as a new therapeutic agent for transhepatic arterial embolisation in liver cancer: preclinical study in a rabbit liver cancer model. J Nucl Med 44:2033–2038

    PubMed  CAS  Google Scholar 

  • Park CH, et al. (1987) Treatment of hepatocellular carcinoma (HCC) with radiolabelled Lipiodol: a preliminary report. Nucl Med Comm 8:1075–1087

    CAS  Google Scholar 

  • Park CH, et al. (1990) Distribution of Lipiodol in hepatocellular carcinoma. Liver 10:72–78

    PubMed  CAS  Google Scholar 

  • Partensky C, et al. (2000) Intra-arterial iodine 131-labeled Lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma. Arch Surg 135:1298–1300

    PubMed  CAS  Google Scholar 

  • Pelletier G, et al. (1990) A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11:181–184

    PubMed  CAS  Google Scholar 

  • Perring S, et al. (1994) Dosimetric assessment of radiolabelled lipiodol as a potential therapeutic agent in colorectal liver métastases using combined CT and SPECT. Nucl Med Comm 15:34–38

    CAS  Google Scholar 

  • Pocock S, White I (1999) Trials stopped early: too good to be true. Lancet 353:943–944

    PubMed  CAS  Google Scholar 

  • Preketes AP, et al. (1996) Pulmonary toxicity following Lipiodol I–131 treatment for liver tumours. Reg Cancer Treat 9:21–26

    Google Scholar 

  • Raoul JL (2001) Lipiocis et carcinome hepatocellulaire. Médecine Nucléaire — imagerie fonctionnelle et métabolique 25:671–674

    Google Scholar 

  • Raoul JL, et al. (1986) L’angiographie lipiodolée au cours des carcinomes hépatocellulaires. Apport du Lipiodol marqué á l’iode 131. J Radiol 67:797–801

    PubMed  CAS  Google Scholar 

  • Raoul JL, et al. (1988) Hepatic artery injection of I–131-labeled Lipiodol. Part 1. Biodistribution study results in patients with hepatocellular carcinoma and liver métastases. Radiology 168:541–545

    PubMed  CAS  Google Scholar 

  • Raoul JL, et al. (1992) Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled Lipiodol. Cancer 69:346–352

    PubMed  CAS  Google Scholar 

  • Raoul JL, et al. (1993) Usefulness of hepatic artery injection of iodized oil and I–131-labeled iodized oil before the therapeutic decision in hepatocellular carcinoma. J Scan Gastroenterol 28:217–223

    CAS  Google Scholar 

  • Raoul JL, et al. (1994) Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 35:1782–1787

    PubMed  CAS  Google Scholar 

  • Raoul JL, et al. ( 1996) Limitations of hyperselective intraarterial injections for the treatment of hepatocellular carcinoma. Invest Radiol 31:305–307

    PubMed  CAS  Google Scholar 

  • Raoul JL, et al. (1997) Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26:1156–1161

    PubMed  CAS  Google Scholar 

  • Raoul JL, et al. (2002) Association of CDDP and intra-arterial injection of 1311-lipiodol (lip 131I) in the treatment of hepatocellular carcinoma (HCC): results of a phase II trial. J Clin Oncol 21:563

    Google Scholar 

  • Raoul JL, et al. (2003) Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol. Br J Surg 90:1379–1383

    PubMed  CAS  Google Scholar 

  • Rindani R, et al. (2002) 131I-lipiodol therapy for unresectable hepatocellular carcinoma. ANZ J Surg 72:210–214

    PubMed  Google Scholar 

  • Risse JH, et al. (2000) Intraarterial HCC therapy with I-131-Lipiodol. Cancer Biother Radiopharm 15:65–71

    Article  PubMed  CAS  Google Scholar 

  • Saito M, et al. (2000) Treatment of roentgenographically occult endobronchial carcinoma with external beam radiotherapy and intraluminal low-dose-rate brachytherapy: second report. Int J Radiat Oncol Biol Phys 47:673–680

    PubMed  CAS  Google Scholar 

  • Salem R, et al. (2004) Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 15(4):335–345

    PubMed  Google Scholar 

  • Sasaki Y, et al. (1985) Changes in distribution of hepatic blood flow induced by intraarterial infusion of angiotensin II in human hepatic cancer. Cancer 55:311–316

    PubMed  CAS  Google Scholar 

  • Shepherd FA, et al. (1992) A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 70:2250–2254

    PubMed  CAS  Google Scholar 

  • Stefanini GF, et al. (1995) Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 75:2427–2434

    PubMed  CAS  Google Scholar 

  • Stubbs RS, et al. (2001) Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology 48:333–337

    PubMed  CAS  Google Scholar 

  • Sundram FX, et al. (2001) 188Rhenium-TDD-lipiodol in treatment of inoperable primary hepatocellular carcinoma — A case report. Ann Acad Med Singapore 30:542–545

    PubMed  CAS  Google Scholar 

  • Sundram FX, et al. (2002) Trans-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma. An IAEA sponsored multi-centre phase 1 study. World J Nucl Med 1:5–11

    Google Scholar 

  • Sundram F, et al. (2003) Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 31:250–257

    Google Scholar 

  • Tan SB, et al. (2002) Following a trial that stopped early: what next for adjuvant hepatic intra-arterial iodine-131 lipiodol in resectable hepatocellular carcinoma. J Clin Oncol 20:1709

    PubMed  CAS  Google Scholar 

  • Tang ZY, et al. (1990) Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second look resection. Cancer 65:211–215

    PubMed  CAS  Google Scholar 

  • Taylor-Robinson SD, et al. (1997) Increase in primary liver cancer in the UK, 1974–94. Lancet 350:1142–1143

    PubMed  CAS  Google Scholar 

  • The CLIP Investigators (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study on 435 patients. Hepatology 28:751–755

    Google Scholar 

  • Tian JH, et al. (1996) Ultrasound-guided internal radiotherapy using yttrium-90-glass microspheres for liver malignancies. J Nucl Med 37:958–963

    PubMed  CAS  Google Scholar 

  • Toubeau M, et al. (2001) 131I thyroid uptake in patients treated with 131I-Lipiodol for hepatocellular carcinoma. Eur J Nucl Med 28:669–670

    PubMed  CAS  Google Scholar 

  • Towu E, et al. (2001) In-vitro uptake of radioactive lipiodol I–131 and I–125 by hepatoblastoma: implications for targeted radiotherapy. Pediatr Surg Int 17:609–613

    PubMed  CAS  Google Scholar 

  • Trinchet JC, Beaugrand M (1999) Augmentation de l’incidence du carcinome hépatocellulaire dans les pays occidentaux. Gastroenterol Clin Biol 23:1286–1288

    PubMed  CAS  Google Scholar 

  • Veilhan LA, et al. (2000) Prevention of recurrence of hepatocellular carcinoma after orthotopic liver transplantation by neoadjuvant intraarterial injections of iodine-131-labelled Lipiodol. Results of a pilot study. Eur J Nucl Med 27:941

    Google Scholar 

  • Wang SJ, et al. (1995) Preparation and biodistribution of yttrium-90 lipiodol in rats following hepatic arterial injection. Eur J Nucl Med 22:233–236

    PubMed  CAS  Google Scholar 

  • Wang SJ, et al. (1996a) Biodistribution of rhenium-188 lipiodol infused via the hepatic artery of rats with hepatic tumours. Eur J Nucl Med 23:13–17

    PubMed  CAS  Google Scholar 

  • Wang SJ, et al. (1996b) Hepatic artery injection of yttrium-90-lipiodol: biodistribution in rats with hepatome. J Nucl Med 37:332–335

    PubMed  CAS  Google Scholar 

  • Wang SJ, et al. (1996c) Radiolabelling of lipiodol with generator produced 188Re for hepatic tumor therapy. Appl Radiat Isot 47:267–271

    PubMed  CAS  Google Scholar 

  • Wang SJ, et al. (2004) A new technique for labeling lipiodol with 188Re in the treatment of hepatic tumor. J Radioanal Nucl Chem 261:189–193

    CAS  Google Scholar 

  • Wheldon TE, et al. (1991) The curability of tumours of differing size by targeted radiotherapy using 1311 or 90Y. Radiother Oncol 21:91–99

    PubMed  CAS  Google Scholar 

  • Yan ZP, et al. (1993) An experimental study and clinical pilot trials on yttrium-90 glass microspheres through the hepatic artery for treatment of primary liver cancer. Cancer 72:3210–3215

    PubMed  CAS  Google Scholar 

  • Yi SW, et al. (1998) Stable lipiodolized emulsions for hepatoma targeting and treatment by transcatheter arterial chemoembolisation. J Control Release 50:135–143

    PubMed  CAS  Google Scholar 

  • Yoo HS, et al. (1989) Radioiodinated fatty acid esters in the management of hepatocellular carcinoma: preliminary findings. Cancer Chemofher Pharmacol 23 (Suppl):S54–S58

    Google Scholar 

  • Yoo HS, et al. (1991) Nodular hepatocellular carcinoma. Treatment with subsegmental intraarterial injection of iodine 131-labeled iodized oil. Cancer 68:1878–1884

    PubMed  CAS  Google Scholar 

  • Yoo HS, et al. (1994) Small hepatocellular carcinoma: high dose internal radiation therapy with super selective intra-arterial injection of I-131-labeled Lipiodol. Cancer Chemother Pharmacol 33(Suppl):S128–S133

    PubMed  Google Scholar 

  • Yu J, et al. (2002) 90Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer. Appl Radiat Isot 58:567–573

    Google Scholar 

  • Yuen MF, et al. (2002) A randomized placebo-controlled study of long acting octreotide fortreatment of hepatocellular carcinoma. Hepatology 36(3):687–691

    PubMed  CAS  Google Scholar 

  • Yumoto Y, et al. (1985) Hepatocellular carcinoma detected by iodized oil. Radiology 154:19–24

    PubMed  CAS  Google Scholar 

  • Yumoto Y, et al. (1992) Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution. Cancer Chemother Pharmacol 31 (Suppl):S128–S136

    PubMed  Google Scholar 

  • Zeng ZC, et al. (1993) Radioimmunotherapy for unresectable hepatocellular carcinoma using 131I-hepama-l mAb: preliminary results. J Cancer Res Clin Oncol 119:257–259

    PubMed  CAS  Google Scholar 

  • Zeng ZC, et al. (1994) Human anti-(murine Ig) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial 131I-labeled hepama-1 mAb. Preliminary results and discussion. Cancer Immunol Immunother 39:332–336

    PubMed  CAS  Google Scholar 

  • Zeng ZC, et al. (1998) Improved long term survival for hepatocellular carcinoma (HCC) with a combination of surgery and hepatic intraarterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials. J Cancer Res Clin Oncol 124: 275–280

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Eugéne Marquis, Rue de la Bataille Flandres-Dunkerque CS 44229, 35042, Rennes Cedex, France

    E. Garin MD, PhD

  2. Medicine Nucléaire, Université de Rennes Centre Eugéne Marquis, Rue de la Bataille des Flandres-Dunkerque, BP 6279, 35062, Rennes Cedex, France

    P. Bourguet MD, PhD

Authors
  1. E. Garin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Bourguet MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Straße 15, D-53127, Bonn, Germany

    Hans-Jürgen Biersack M.D. (Professor and Chairman) (Professor and Chairman)

  2. Nuclear Medicine and Radiology, Albert Einstein College of Medicine Director, Dept. of Nuclear Medicine Montefiore Medical Centre/Moses Division, 111 East 210th Street, Bronx, NY, 10467, USA

    Leonard M. Freeman M.D. (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Garin, E., Bourguet, P. (2007). Intra-arterial Therapy of Liver Tumours. In: Biersack, HJ., Freeman, L.M. (eds) Clinical Nuclear Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-28026-2_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-28026-2_27

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28025-5

  • Online ISBN: 978-3-540-28026-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation